In conclusion, our findings shed light on the crucial role of the α4β7/MAdCAM-1 axis in regulating hepatic fibrosis and highlight the potential therapeutic strategy of utilizing mAbs targeting integrin α4β7 or MAdCAM-1 to treat inflammation and fibrosis in CLD. This evidence concerns the gene MADCAM1 and congenital secretory chloride diarrhea 1.